Literature DB >> 17639046

Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202.

Manali Mody1, Nachiket Dharker, Mark Bloomston, Pei-Shan Wang, Fu-Sheng Chou, Theodore S Glickman, Timothy McCaffrey, Zhaoqing Yang, Anne Pumfery, Daniel Lee, Matthew D Ringel, Joseph J Pinzone.   

Abstract

Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a member of the nuclear hormone superfamily and has multiple endogenous and pharmacological ligands, including 15-deoxy-Delta (12,14)-prostaglandin J(2) and two thiazolidinediones (TZD), rosiglitazone and pioglitazone, which are used clinically to treat type-2 diabetes mellitus. PPARgamma agonists regulate development, cellular growth and metabolism in various tissues and have been documented to decrease cellular proliferation and to induce apoptosis of various tumour phenotypes, including breast cancer. However, the full spectrum of anti-tumour effects occurs only at suprapharmacological doses. In this study, we investigated the mechanism of rosiglitazone-induced anti-tumour effects of MDA-MB-231 human breast cancer cells, and used that information to predict rosiglitazone-induced sensitization of breast cancer cells to the effects of other compounds. We first confirmed that 100 microM rosiglitazone, but not lower doses, decreases MDA-MB-231 cell viability in vitro. We then used microarray gene expression analysis to determine early rosiglitazone-induced gene expression changes after 4-h exposure, which included 1298 genes that we grouped into functional categories. We selectively confirmed rosiglitazone-mediated effects on expression of key regulators of breast cancer proliferation and apoptosis, including p53, p21 and Bax. Finally, we used this information to predict that rosiglitazone would sensitize MDA-MB-231 cells to the anti-tumour effects of CH11, which trimerizes Fas, as well as tumour necrosis factor-alpha. Moreover, we used the confirmed array data to predict cooperative activity of rosiglitazone and R-roscovitine (CYC202), an inhibitor of multiple cyclin-dependent kinases. We conclude that microarray analysis can determine early TZD-modulated changes in gene expression that help to predict effective in vitro drug combinations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639046     DOI: 10.1677/ERC-06-0003

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  13 in total

1.  PPARgamma activation induces autophagy in breast cancer cells.

Authors:  Jie Zhou; Wei Zhang; Bing Liang; Mathew C Casimiro; Diana Whitaker-Menezes; Min Wang; Michael P Lisanti; Susan Lanza-Jacoby; Richard G Pestell; Chenguang Wang
Journal:  Int J Biochem Cell Biol       Date:  2009-06-26       Impact factor: 5.085

2.  Promotion of breast cancer cells MDA-MB-231 invasion by di(2-ethylhexyl)phthalate through matrix metalloproteinase-2/-9 overexpression.

Authors:  Shuya Zhang; Jiehua Ma; Ziyi Fu; Zhilei Zhang; Jian Cao; Lei Huang; Wenqu Li; Pengfei Xu; Xin Cao
Journal:  Environ Sci Pollut Res Int       Date:  2016-02-06       Impact factor: 4.223

Review 3.  Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs.

Authors:  Toshikatsu Okumura
Journal:  J Gastroenterol       Date:  2010-09-08       Impact factor: 7.527

4.  Modification of MCF-10A cells with pioglitazone and serum-rich growth medium increases soluble factors in the conditioned medium, likely reducing BT-474 cell growth.

Authors:  Boon Yin Khoo; Noorizan Miswan; Prabha Balaram; Kalpanah Nadarajan; Elena Elstner
Journal:  Int J Mol Sci       Date:  2012-05-10       Impact factor: 6.208

5.  A Role for the PPARgamma in Cancer Therapy.

Authors:  Moray J Campbell; Carsten Carlberg; H Phillip Koeffler
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

6.  Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARγ.

Authors:  Kumar Nikhil; Shruti Sharan; Abhimanyu K Singh; Ajanta Chakraborty; Partha Roy
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

7.  Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231.

Authors:  Mariel Núñez; Vanina Medina; Graciela Cricco; Máximo Croci; Claudia Cocca; Elena Rivera; Rosa Bergoc; Gabriela Martín
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-11       Impact factor: 2.483

8.  The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.

Authors:  Graham Skelhorne-Gross; Christopher J B Nicol
Journal:  PPAR Res       Date:  2012-07-02       Impact factor: 4.964

9.  PPARgamma and Apoptosis in Cancer.

Authors:  Heath A Elrod; Shi-Yong Sun
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

Authors:  Ancha Baranova
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.